Answers are grounded in this paper and cite their sources.
Analysis reports that none of five U.S. cannabis products with THC-JD labels contained the compound, highlighting consumer safety issues.
THC-JD is a semi-synthetic cannabinoid with an eight-carbon C3 side chain, present in only trace amounts in hemp, requiring synthesis for commercial use. It has been promoted as potentially 19 times more potent than Δ⁹-THC, consistent with enhanced CB1 receptor affinities for cannabinoids with 7-8 carbon C3 side chains. While one peer-reviewed report identified THC-JD in Japanese online products, an anecdotal report from the U.S. suggests mislabeling. To inform regulatory efforts and consumer awareness, and to address these discrepancies, this study chemically analyzed five U.S. commercial cannabis vape products marketed as containing THC-JD. Utilizing GC-MS analysis with a Δ⁸-THC-JD reference standard, no THC-JD was detected in any of the five commercial samples. Instead, the most prevalent compound in four of the five samples was Δ⁸-THC. The absence of THC-JD in these products raises critical concerns for consumer safety, regulatory compliance, and industry integrity, as consumers risk unknowingly ingesting uncharacterized or mislabeled substances. This unpredictability increases the likelihood of acute intoxication and other adverse outcomes, while also undermining trust in the industry and potentially accelerating calls for more rigorous regulatory oversight.
No takes yet. Share an insight, caveat, or question.
Munger et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: